Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Santin is a methoxylated flavonoid, chemically identified as 5,7-dihydroxy-3,6,4'-trimethoxyflavone, which is naturally found in plants such as *Varthemia iphionoides*. It is currently being investigated as a bioactive lead compound for the treatment of metastatic prostate cancer. Santin demonstrates cytotoxic properties in prostate cancer cell lines, including PC3 and DU145, by modulating mitochondrial function and cell-cycle progression. Research indicates that it induces apoptosis through mitochondrial membrane potential depolarization and perturbation of cell-cycle dynamics, making it a candidate for further ADMET profiling and drug development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on santin.